DPP4 and hypertriglyceridemia: However, this was the first study to evaluate the effects of DPP-4 inhibitor, statin, and n-3 PUFA combination therapy on lipoprotein particle and glycemic control in patients with type 2 diabetes and hypertriglyceridemia.